Medication leaflets

Active substance

Results for the substance semaglutide

20 results

About this active substance

Semaglutide is a medication used to treat type 2 diabetes and, in some cases, to manage body weight in patients with obesity or overweight. It belongs to the class of GLP-1 receptor agonists (glucagon-like peptide-1), which work by stimulating insulin secretion, reducing glucagon secretion, and slowing gastric emptying, thereby lowering blood sugar levels and reducing appetite.

Semaglutide is available as a subcutaneous injection (administered once weekly) or, in some cases, as oral tablets. It is used in combination with a healthy diet and exercise to improve glycemic control and, in the case of obesity treatment, to support weight loss.

Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain, especially at the start of treatment. In rare cases, it may cause pancreatitis, hypoglycemia (particularly when used with other antidiabetic medications), or thyroid problems.

Semaglutide is not recommended for patients with a history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2). It is important for patients to follow their doctor's recommendations and monitor for any adverse reactions.